The unmentionables...and hidden from view

As of April 2, 2025, liraglutide remained in shortage, with the drug first entering the FDA database on July 18, 2023.

As artificial intelligence evolves from a novel technology to commonplace in health care, the pharmacy industry is adapting to its challenges and opportunities.

Denosumab-bnht (Conexxence, Bomyntra) became the third biosimilar in 2025 to be approved for denosumab (Prolia, Xgeva).

From market pressures to regulatory framework, Eric Tichy, PharmD, MBA, BCPS, FCCP, FAST, discussed growth in the business of health-system pharmacy and the challenges it has faced.

Chichi Ilonzo Momah, PharmD, discussed what pharmacists can be doing to address vaccine hesitancy and the barriers impeding under-resourced communities.

The decision makes the RNAi therapeutic the only therapy approved by the FDA to treat ATTR-CM and hATTR-PN.